-+ 0.00%
-+ 0.00%
-+ 0.00%

Okanvision Bio-B (01477.HK) announced that the phase III clinical trial of OT-211 (TRYPTYR® acotrimene eye drops) in the People's Republic of China has recently completed enrolling a total of 398 patients.

Zhitongcaijing·09/02/2026 12:17:09
Listen to the news
Okanvision Bio-B (01477.HK) announced that the phase III clinical trial of OT-211 (TRYPTYR® acotrimene eye drops) in the People's Republic of China has recently completed enrolling a total of 398 patients.